Dr Andrew Chantry

Leukaemia Research Fund Clinical Research Fellow

Academic Unit of Bone Biology
School of Medicine and Biomedical Sciences
University of Sheffield
D Floor Medical School
Beech Hill Road
S10 2JF

Tel: +44 (0)114 2712375
Fax: +44 (0)114 2711711
Email: a.d.chantry@sheffield.ac.uk

Research Interests

I am researching the mechanisms of myeloma bone disease. In particular, I am investigating the inhibition of osteoblast function in myeloma bone disease focusing on Dkk1 and the Wnt signalling pathway and the activin/inhibin pathway.

Activities and Distinctions

Bone Research Society, New Investigator´s Award – July 2007
Leukaemia Research Fund Clinical Research Fellowship of the Year 2005

Representative Publications

ApomineTM, an inhibitor of HMG-CoA-Reductase, Promotes Apoptosis of Myeloma Cells In Vitro and is Associated with a Modulation of Myeloma In Vivo. Claire M. Edwards, Gabrielle Mueller, Anke J. Roelofs, AD Chantry, M Perry, R. Graham, G. Russell, B Van Camp, Y Guyon-Gellin, EJ Niesor, CL Bentzen, K Vanderkerken, PI Croucher. International Journal of Cancer July 2007

Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-κB ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma. E Terpos, D Heath, ADChantry, A Rahemtulla, A Anagnostopoulos, A Pouli, E Katadritou, E Verrou, E Vervessou, M Dimopoulos and PI Croucher. British journal of Haematology Dec 2006

Long term outcomes of myeloablation and autologous transplantation of relapsed acute myeloid leukaemia in second remission: a British Society of Blood and Marrow Transplantation Registry Study. AD Chantry, JA Snowden, C Craddock, K Peggs, C Roddie, J Craig, K Orchard, K. Towlson, RM Pearce, DI Marks. Biology of Blood and Marrow Transplantation Dec 2006

Current Grants

Leukaemia Research Fund £162,890 (2005)
Wnt signalling and the development of myeloma bone disease: Studies of the role of dickkopf 1 (DKK1) and soluble frizzled related protein-3 (sFRP3). LRF Clinical Research Fellow Award.
Dr A.D. Chantry

Leukaemia Research Fund £314,061 (2008)
Defining the role of Dickkopf1 (DKK1) in the development of myeloma bone disease. LRF/Academy of Medical Sciences Clinician Scientist Award
Dr A.D. Chantry